February 29, 2024
Pfizer Japan said on February 28 that it has submitted a new drug application with Japanese regulatory authorities for marstacimab for the reduction of bleeding episodes in hemophilia patients without inhibitors to factor VIII (FVIII) or factor IX (FIX). The...read more